Alivus Life Sciences Ltd Share Price
As on 11 December 2025 at 02:07 IST
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-4.56%
Over 6 Months
-13.43%
Over 1 Year
-14.68%
Over 3 Years
105.74%
Alivus Life Sciences Ltd Summary
Close ₹878.60
Open ₹850.70
High ₹885.85
Low ₹849.60
Volume 76,473
Net Turnover (in Cr) ₹6.65
52Wk High ₹1,251
52Wk Low ₹847.20
52Wk High / Low
847.20
1,251
Alivus Life Sciences Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹10,778.78
EPS (TTM) 43.23
Book Value (BV) 245.79
Div. Yield 0.57 %
P/E (TTM) 20.34
Price/Book Value 3.58
Delivery % 42.83 %
Face Value 2
Key Ratios
PE Ratio 27.24
PB Ratio 4.70
EV to Sales 5.54
PEG Ratio 8.72
ROA 16.79
ROE 18.86
Debt-Equity 0.01
Net Profit Margin 20.35
Operating Profit Margin 30.05
Alivus Life Sciences Ltd Financials
Profit and Loss
No data available
Balance Sheet
No data available
Cash Flow
No data available
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 2,421.45 | 2,295.26 | 2,190.18 | 2,137.92 | 1,885.98 |
| Total Expenses | 1,767.32 | 1,663.97 | 1,561.57 | 1,572.99 | 1,415.03 |
| Profit Before Tax | 654.13 | 631.29 | 628.61 | 564.92 | 470.94 |
| Profit After Tax | 485.63 | 470.89 | 466.96 | 418.72 | 351.58 |
| Operating Profit After Depreciation | 656.54 | 632.84 | 629.16 | 592.89 | 558.49 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 962.61 | 809.87 | 792.89 | 595.03 | 572.80 |
| Total Non Current Assets | 1,076.30 | 934.41 | 851.81 | 706.42 | 598.03 |
| Total Current Assets | 2,335.16 | 1,916 | 1,850.34 | 1,764.58 | 1,399.04 |
| Total Assets | 3,411.45 | 2,850.41 | 2,702.15 | 2,471.01 | 1,997.08 |
| Total Shareholder's Fund | 2,817.37 | 2,332.32 | 2,138.21 | 2,054.31 | 752.75 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 391.52 | 413.52 | 306.01 | 597.59 | 388.11 |
| Net Cash Used In Investing Activities | -615.65 | -116.48 | -146.75 | -122.23 | -68.73 |
| Net Cash Used In Financing Activities | -6.23 | -279.44 | -387.59 | -78.80 | -213.78 |
No data available
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 587.98 | 601.85 | 649.55 | 641.84 | 506.88 |
| Total Expenses | 408.81 | 429.54 | 451.11 | 451.54 | 372.52 |
| Profit Before Tax | 174.13 | 162.99 | 191.30 | 185.14 | 127.46 |
| Profit After Tax | 130.03 | 121.54 | 141.87 | 136.96 | 95.32 |
| Operating Profit after Depreciation | 193.89 | 181.30 | 208.53 | 200.76 | 142.89 |
Alivus Life Sciences Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 856.85
S2 835.10
S3 820.60
Pivot 871.35
R1 893.10
R2 907.60
R3 929.35
Moving Average
20 SMA 897.75
50 SMA 912.86
100 SMA 944.10
200 SMA 992.15
Alivus Life Sciences Ltd Corporate Actions
Alivus Life Sciences Ltd
₹5.0/Share
Announcement Date 01 Sep 2025
Record Date 01 Sep 2025
Div Yield 250%
Alivus Life Sciences Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,776.20 | ₹4,26,169.88 |
| Divis Laboratories Ltd | ₹6,292.20 | ₹1,67,038.14 |
| Torrent Pharmaceuticals Ltd | ₹3,763 | ₹1,27,351.30 |
| Cipla Ltd | ₹1,490.70 | ₹1,20,414.46 |
| Dr Reddys Laboratories Ltd | ₹1,246.25 | ₹1,04,014.67 |
Alivus Life Sciences Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Quant Healthcare Fund | 5.85% |
| Old Bridge Focused Fund | 3.45% |
| Helios Small Cap Fund | 1.52% |
| Quant Flexi Cap Fund | 1.42% |
| Quantum Small Cap Fund | 1% |
Alivus Life Sciences Ltd News
Alivus Life Sciences announces board meeting date
On 6 November 2025
30 Oct 2025, 10:27 am
Alivus Life Sciences to conduct AGM
On 8 September 2025
12 Aug 2025, 12:09 pm
Alivus Life Sciences to declare Quarterly Results
On 1 August 2025
25 Jul 2025, 11:06 am
Board of Alivus Life Sciences recommends final dividend
Of Rs 5 per share
16 May 2025, 09:27 am
Alivus Life Sciences to hold board meeting
On 15 May 2025
09 May 2025, 10:57 am
Alivus Life Sciences Ltd Stock Analysis
- Annual revenue for Alivus Life Sciences Ltd increased by 5.50% to ₹2,421.45 crore in FY 2025 from ₹2,295.26 crore in FY 2024.
- Annual Net Profit for Alivus Life Sciences Ltd increased by 3.13% to ₹485.63 crore in FY 2025 from ₹470.89 crore in FY 2024.
- Promoter Shareholding in Alivus Life Sciences Ltd decreased by 0.04% in the most recent quarter, from 74.94% in June 2025 to 74.91% in September 2025.
- Alivus Life Sciences Ltd delivered a 1-year return of -14.68% compared to the Nifty 50, which provided a return of 4.96% as of the last trading session.
- Alivus Life Sciences Ltd share price moved up by 0.71% from its previous close of INR ₹878.60. The latest Alivus Life Sciences Ltd share price is INR ₹884.85.
- Alivus Life Sciences Ltd share price today has been at a low of 876 and a high of 894.55. Over the past 52 weeks, the Alivus Life Sciences Ltd share price has seen a low of 847.20 and a high of 1,251.
FAQ’s
What is the share price of Alivus Life Sciences Ltd today?
Alivus Life Sciences Ltd share price as on 10 Dec 2025 is ₹ 884.85
What is the Market Cap of Alivus Life Sciences Ltd?
The market cap of Alivus Life Sciences Ltd stock is ₹10,778.78 Cr.
What is the PE Ratio of Alivus Life Sciences Ltd?
The Price to Earnings (P/E) Ratio of Alivus Life Sciences Ltd is 27.24
What is the PB Ratio of Alivus Life Sciences Ltd?
The Price to Book (P/B) Ratio of Alivus Life Sciences Ltd is 4.70
What is the 52 week high of Alivus Life Sciences Ltd Share Price?
The 52 week high of Alivus Life Sciences Ltd share price stands at ₹1,251
What is the 52 week low of Alivus Life Sciences Ltd Share Price?
The 52 week low of Alivus Life Sciences Ltd share price stands at ₹847.20
How can I buy shares of Alivus Life Sciences Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Alivus Life Sciences Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
